Equities

Hikma Pharmaceuticals PLC

HIK:LSE

Hikma Pharmaceuticals PLC

Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1,950.00
  • Today's Change78.00 / 4.17%
  • Shares traded406.77k
  • 1 Year change11.05%
  • Beta0.3862
Data delayed at least 20 minutes, as of Nov 22 2024 16:38 GMT.
More ▼

Profile data is unavailable for this security.

About the company

Hikma Pharmaceuticals PLC is a pharmaceutical company. The principal activities of the Company are the development, manufacture and marketing of a range of generic, branded and in-licensed pharmaceutical products. The Company operates through three segments: Injectables, Branded and Generics. The Injectables segment supplies hospitals across its markets with generic injectable products, supported by its manufacturing facilities in the United States, Europe and Middle East/North Africa (MENA). It is also engaged in the finished dosage form (FDF) business and has a manufacturing facility in Cleveland, Ohio. The Branded segment supplies branded generics and in-licensed patented products from its local manufacturing facilities to retail and hospital customers across the MENA region. The Generics segment supplies oral and other non-injectable generic and specialty products to the United States retail market, leveraging its manufacturing facility in Columbus, Ohio.

  • Revenue in GBP (TTM)2.40bn
  • Net income in GBP226.44m
  • Incorporated2005
  • Employees8.97k
  • Location
    Hikma Pharmaceuticals PLC1 New Burlington PlaceLONDON W1S 2HRUnited KingdomGBR
  • Phone+44 20 7399 2760Fax+44 20 7399 2761
  • Websitehttps://www.hikma.com/
More ▼

Peer analysis

CompanyRevenue (TTM)Net income (TTM)Market capEmployeesMarket Cap /
Employees
Axsome Therapeutics Inc268.85m-247.00m3.74bn545.003.74bn545.00
IPCA Laboratories Ltd802.18m62.15m3.75bn17.34k3.75bn17.34k
GlaxoSmithKline Pharmaceuticals Limited334.70m63.46m3.77bn3.21k3.77bn3.21k
Krka d.d. Novo Mesto1.58bn299.39m3.78bn11.75k3.78bn11.75k
Glenmark Pharmaceuticals Ltd1.15bn-95.73m3.89bn14.99k3.89bn14.99k
ADMA Biologics Inc304.08m54.12m4.00bn624.004.00bn624.00
Avidity Biosciences Inc8.04m-222.80m4.03bn253.004.03bn253.00
Richter Gedeon Vegyeszeti Gyar Nyrt1.64bn463.54m4.08bn11.60k4.08bn11.60k
Hikma Pharmaceuticals Plc2.40bn226.44m4.17bn8.97k4.17bn8.97k
Humanwell Healthcare Group Co Ltd2.80bn214.62m4.26bn17.68k4.26bn17.68k
Siegfried Holding AG1.15bn114.88m4.46bn3.80k4.46bn3.80k
Ono Pharmaceutical Co Ltd2.49bn488.97m4.48bn3.85k4.48bn3.85k
Data as of Nov 22 2024. Currency figures normalised to Hikma Pharmaceuticals PLC's reporting currency: UK Pound GBX

Institutional shareholders

25.37%Per cent of shares held by top holders
HolderShares% Held
Wellington Management Co. LLPas of 31 Dec 202311.56m5.21%
JPMorgan International Bank Ltd.as of 01 Nov 202410.75m4.84%
Capital Research & Management Co. (World Investors)as of 01 Nov 20246.93m3.12%
BlackRock Advisors (UK) Ltd.as of 31 Dec 20236.15m2.77%
Mawer Investment Management Ltd.as of 30 Jun 20244.86m2.19%
The Vanguard Group, Inc.as of 01 Nov 20244.23m1.90%
Royal London Asset Management Ltd.as of 01 Nov 20243.14m1.41%
Polar Capital LLPas of 30 Sep 20243.06m1.38%
Threadneedle Asset Management Ltd.as of 31 Aug 20243.01m1.36%
Norges Bank Investment Managementas of 01 Nov 20242.62m1.18%
More ▼
Data from 30 Jun 2024 - 01 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on InvestorsChronicle.co.uk is subject to the Investors Chronicle Terms & Condition
All content on InvestorsChronicle.co.uk is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by IC and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via Investors Chronicle is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. Investors Chronicle is not responsible for any use of content by you outside its scope as stated in the Investors Chronicle Terms & Condition.